Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3093399 | 0.94 | DYRK1A (0.42) | NR1H4MEN1KMT2ATP53RAB9A | |
| SCHEMBL3093456 | 0.94 | NR1H4 (0.46) | NR1H4TP53NPC1SMN1; SMN2DYRK1A | |
| SCHEMBL3098705 | 0.86 | NR1H4 (0.48) | NR1H4MEN1KMT2ATP53RAB9A | |
| SCHEMBL3109612 | 0.85 | DYRK1A (0.39) | MEN1KMT2ATP53RAB9ASMN1; SMN2 | |
| SCHEMBL3093465 | 0.80 | NR1H4 (0.51) | NR1H4MEN1KMT2ATP53RAB9A | |
| SCHEMBL3093410 | 0.80 | APP (0.46) | NR1H4RAB9ANPC1POLBKDM4E | |
| SCHEMBL3093467 | 0.79 | DYRK1A (0.40) | NR1H4MEN1KMT2ATP53RAB9A | |
| SCHEMBL3099130 | 0.78 | DYRK1A (0.43) | NR1H4MEN1KMT2ATP53RAB9A | |
| SCHEMBL3104751 | 0.78 | DYRK1A (0.43) | MEN1KMT2ATP53RAB9ANPC1 | |
| SCHEMBL3099171 | 0.78 | DYRK1A (0.42) | NR1H4MEN1KMT2ATP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188078-B2 | 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particular as C-MET inhibitors | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| US-20100273793-A1 | 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS | SANOFI-AVENTIS (FR) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273793-A1 | 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS | MET, ALK, JAK2 | NR1H4 710/4885MEN1 842/4885KMT2A 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.